Similar articles

• [The value of incretin based therapies].

  Gallwitz B. Gallwitz B. Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6. Dtsch Med Wochenschr. 2009. PMID: 19421931 Review. German. No abstract available.
• Distinguishing among incretin-based therapies. Introduction.

  Campbell RK, Cobble ME, Reid TS, Shomali ME. Campbell RK, et al. J Fam Pract. 2010 Sep;59(9 Suppl 1):S3-4. J Fam Pract. 2010. PMID: 20824238
• Incretin physiology and its role in type 2 diabetes mellitus.

  Svec F. Svec F. J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS20-4. J Am Osteopath Assoc. 2010. PMID: 20644202 Review.
• Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

  Jellinger PS. Jellinger PS. Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Postgrad Med. 2011. PMID: 21293084 Review.
• [Therapeutic use and adverse events of incretin-related drugs].

  Ishikawa M, Yamada Y. Ishikawa M, et al. Nihon Rinsho. 2012 May;70 Suppl 3:699-702. Nihon Rinsho. 2012. PMID: 22768601 Japanese. No abstract available.